<![CDATA[NF1-PN Treatment Goals and Quality of Life Impact]]>
Post Content: Source: Neurology Read More
<![CDATA[NF1 Diagnostic Criteria and Clinical Recognition]]>
Post Content: Source: Neurology Read More
<![CDATA[CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease]]>
Post Content: Source: Neurology Read More
<![CDATA[Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement]]>
<![CDATA[NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease]]>
What APA Is Doing for You: Update on Clozapine REMS
In November 2021, the Food and Drug Administration (FDA) instituted a new Clozapine Risk Evaluation and Mitigation Strategy (REMS) to…
Read More
